000168596 001__ 168596
000168596 005__ 20260211123813.0
000168596 0247_ $$2doi$$a10.3390/pharmaceutics18020193
000168596 0248_ $$2sideral$$a147954
000168596 037__ $$aART-2026-147954
000168596 041__ $$aeng
000168596 100__ $$aMarco-Brualla, Joaquín
000168596 245__ $$aThe Combination of Immunomodulatory Secretome and Liposome-Bound TRAIL Improves Knee Osteoarthritis Symptoms in an Ovine Model
000168596 260__ $$c2026
000168596 5060_ $$aAccess copy available to the general public$$fUnrestricted
000168596 5203_ $$aBackground/Objectives: Knee osteoarthritis stands as the highest prevalent joint disease worldwide, affecting millions of adults and significantly impairing mobility and quality of life. Pro-inflammatory cells and cytokines are considered key players in the pathophysiology of the disease. In previous work, two anti-inflammatory therapeutic approaches were developed: a secretome enriched in anti-inflammatory cytokines, and nanoliposome-bound TRAIL (LUV-TRAIL), with proven efficacy against rheumatoid arthritis in rabbits. Methods: In this work, we evaluated the ability of these treatments to prevent the development of osteoarthritis (OA) in an ovine model following meniscectomies. Two weeks after the surgeries, knees were treated with several rounds of single or combined therapy, and then sheep were left untreated for several months. Knee damage was followed by X-ray analysis and, after sacrifice, assessed through macroscopic inspection, histological determinations, and inflammatory cytokine measurements. Results: The combined therapy had a significant positive effect against osteoarthritis development. Specifically, the combination is capable of improving knee injury in the first stages of OA in several parameters, such as synovial hyperplasia and tibial plateau damage, which are two of the most frequently damaged areas. Other markers, such as synovial inflammation and X-ray and macroscopic images, also presented a tendency to improved scores. Conclusions: The combination of the secretome with LUV-TRAIL represents a promising therapy worth exploring further in osteoarthritis treatment and/or prevention.
000168596 536__ $$9info:eu-repo/grantAgreement/ES/DGA/B31-20R$$9info:eu-repo/grantAgreement/ES/DGA/B23-20R$$9info:eu-repo/grantAgreement/ES/UZ/OTRI-2022-0396
000168596 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttps://creativecommons.org/licenses/by/4.0/deed.es
000168596 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000168596 700__ $$aGarcía-Álvarez, Felícito
000168596 700__ $$aFuente, Sara$$uUniversidad de Zaragoza
000168596 700__ $$aFernández, Pablo
000168596 700__ $$0(orcid)0000-0003-1286-4968$$aVitoria, Arantza$$uUniversidad de Zaragoza
000168596 700__ $$0(orcid)0000-0002-8712-2275$$aVázquez, Francisco José$$uUniversidad de Zaragoza
000168596 700__ $$aLapuente-Fernández, Juan Pedro
000168596 700__ $$0(orcid)0000-0003-3043-147X$$aMartínez-Lostao, Luis$$uUniversidad de Zaragoza
000168596 700__ $$0(orcid)0000-0001-7188-0461$$aRomero, Antonio$$uUniversidad de Zaragoza
000168596 700__ $$0(orcid)0000-0002-5175-8394$$aAnel, Alberto$$uUniversidad de Zaragoza
000168596 7102_ $$11011$$2566$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Inmunología
000168596 7102_ $$11002$$2060$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Bioquímica y Biolog.Mole.
000168596 7102_ $$11009$$2617$$aUniversidad de Zaragoza$$bDpto. Patología Animal$$cÁrea Medicina y Cirugía Animal
000168596 773__ $$g18, 2 (2026), 193 [21 pp.]$$pPharmaceutics$$tPharmaceutics$$x1999-4923
000168596 8564_ $$s4730495$$uhttps://zaguan.unizar.es/record/168596/files/texto_completo.pdf$$yVersión publicada
000168596 8564_ $$s2441555$$uhttps://zaguan.unizar.es/record/168596/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000168596 909CO $$ooai:zaguan.unizar.es:168596$$particulos$$pdriver
000168596 951__ $$a2026-02-11-10:27:56
000168596 980__ $$aARTICLE